Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The company has a number of proprietary drug product candidates that are currently in clinical trials.

The company today announced it has completed the enrollment of 292 patients in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of the Zalicus’ Synavive drug. Synavive is a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits in patients with rheumatoid arthritis.

The trial is a 12-week, five-arm, global, double-blind, placebo-controlled study designed to evaluate the company’s Synavive drug as a treatment for the signs and symptoms of rheumatoid arthritis in subjects with moderate to severe disease. The study is being conducted in up to 60 sites throughout the United States, Europe, and Latin America. The primary goal of the trial is to see the efficacy of Synavive versus a placebo, as well as compared to Prednisone and Dipyramidamole. The results of the study are expected in the third quarter of this year.

Patients who complete the SYNERGY trial are eligible to participate in a one-year extension study to evaluate the long-term safety and durability of response for Synavive. For additional information about Synavive and Zalicus’ other drug candidates, please visit the company’s website at www.zalicus.com

Let us hear your thoughts below: